BPI Contributor

November 1, 2012

3 Min Read

This is the only event in Japan with coverage of all oligonucleotide classes: RNAi, peptide therapeutics, and vaccines. AsiaTIDES continues to be the premier forum where attendees get a comprehensive update, meet key players, and increase their knowledge of the oligonucleotide- and peptide-based therapeutics fields.

BPI_A_121010AR09_O_185820a.jpg




BPI_A_121010AR09_O_185821a.jpg




Hear the latest reports from RXi, Tekmira, Santaris, miRagen, Arrowhead, REPLICor, Noxxon, Silence, PeptiDream, Pfizer, Immunovaccine, OncoTherapy Science, Zealand, Radius, Aileron, and more. Learn manufacturing capabilities of all the major oligonucleotide and peptide contract manufacturing organizations (CMOs). For updates on science, business developments, and regulatory changes — as well as practical tutorials — this event is your best conference choice to update your knowledge in all the relevant areas in just three days.

Many presentations throughout the program will include unpublished data first heard at AsiaTIDES. Gain a competitive edge by hearing first-hand unpublished data from our panel of industry-leading speakers.

Networking

There are over five exhibit hall hours incorporated in the program allowing you plenty of time to meet with exhibitors and attendees. Take advantage of a more relaxed networking setting by attending the networking dinner on Tuesday night (cosponsored by ChemGenes). More than 20 exhibitors will be in a bustling exhibit hall. They are ready to answer your questions so you can get up to speed on products and services that will advance your process development and manufacturing.

New for 2013

Hear reports from Japanese companies on their US collaborations. See the first joint session presented by OSWG and JPMA on preclinical and clinical safety assessment for planning regulatory strategies.

Preconference Tutorials

Start your conference experience on Tuesday 26 February 2013 at 8:30 AM with learning opportunities offered only at AsiaTIDES.

Tutorial #1: “Quality by Design (QbD) and In-Process Control (IPC) Requirements and Analytical Methods to Control Product Quality,” led by Mimoun Ayoub (vice president of global business, sales, and strategic development at Peptisyntha SA) and Robert Hagopian (director of business development at PolyPeptide Laboratories)

Tutorial #2: “Approaches to Successful Delivery of Oligonucleotides in vivo: Chemical Modifications and DDS (Drug Delivery Systems)” led by Dmitry Samarsky (executive vice president of technology development at RiboBio)

Keynotes

“Oligonucleotide Therapeutics: The Third Platform for Drug Development,” by Arthur M. Krieg (chief executive officer at RaNA Therapeutics)

“Development of Lipid Nanoparticle (LNP) Based Delivery System of siRNA Targeting Extrahepatic Tumor,” by Etsuo Ohshima (managing officer and vice president, head of the research division at Kyowa Hakko Kirin Co., Ltd.)

“Defying Difficult Diseases: Protease Inhibitors and the Click Peptide Concept Using O-Acyl Isopeptides,” by Yoshiaki Kiso (professor in the laboratory of peptide science at the Nagahama Institute of Bio-Science and Technology)

“The Journey Together: Omontys (Peginesatide) — from Bench to Bedside,” by Ping Qiu (senior medical director of clinical science at Takeda Global Research and Development Inc.)

“Antisense Oligonucleotide Therapy for the Treatment of Neurodegenerative Diseases,” by C. Frank Bennett (senior vice president of research at Isis Pharmaceuticals)

Sessions

After the keynote presentations, sessions include updates on

  • Oligonucleotide-Based Therapeutics in Preclinical Development

  • Oligonucleotide-Based Therapeutics in Clinical Development

  • Peptide-Based Therapeutics in Preclinical Development

  • Peptide-Based Therapeutics in Clinical Development

  • Peptide-Based Therapeutics and Vaccines in Clinical Development

Other sessions will focus on

  • Manufacturing and Analytical Development for Peptides and Oligos

  • DDS (Drug Delivery Systems) for Peptides and Oligonucleotides

  • Business Considerations (including a report from Excaliard on their acquisition by Pfizer)

  • OSWG and JPMA Joint Session: Preclinical and Clinical Safety Assessment of Oligonucleotides

Testimonials

“The preeminent conference in Japan on the development of therapeutic oligos and peptides … brings together a majority of the leaders in the field.” —Patrick C. Reid (chief scientific officer at PeptiDream)

“AsiaTIDES is a well-organized, informative meeting providing a great overview of the oligonucleotide field and the opportunity to network with current and potential collaborators in a nice setting.” —Pamela A. Pavco (chief development officer at RXi Pharmaceuticals)

You May Also Like